\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
Laboratory-grade, instrument-free Veros™ COVID-19 molecular test available now
BOSTON
Veros COVID-19, autonomous and single-use, produces PCR-grade effects in approximately 15 minutes, with no drive restrictions or external force requirements. TECOmedical, a Eurobio Scientific company, is a leading specialist medical distributor opening new markets with state-of-the-art technology. Effective in Germany and Austria, and awaiting regulatory approval in Switzerland, the deal is the newest of Sense’s planned distribution partnerships in the EU as it markets its Veros platform.
“We are excited to partner with TECOmedical to bring Veros COVID-19 to market, building on the impressive reputation TECOmedical has built with its consumers,” said Ryan Roberts, Chief Commercial Officer of Sense. “We are confident that by adding Veros COVID-19 without -19 instruments to their diagnostic portfolio, TECOmedical consumers will gain advantages from laboratory-grade molecular control that can provide greater access and faster diagnosis, helping them deliver care to their patients directly at the point of use. “
“We are looking for cutting-edge technologies that respond to an unmet need,” said Marieluise Wippermann, CEO of TECOmedical. “Being able to deliver an instrument-free PCR grade result in minutes directly to the point of service reflects our commitment as consumers to provide answers that help them overcome the limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and look forward to an expanded Veros verification menu in the future. “
Veros is the first and only fast, single-use, instrument-free, point-of-service molecular diagnostic testing platform that produces laboratory effects in approximately 15 minutes. Using patented immediate molecular amplification technology, Veros aims to access immediate testing and high-precision point-of-care testing for more people and slow the spread of COVID-19 through faster, more accurate diagnostics.
The clinical functionality of Veros COVID-19 has been established in one of the most comprehensive clinical trials of COVID-19 diagnostic tests conducted to date. The multicenter study prospectively recruited nearly three hundred evaluable subjects, the Delta and Omicron variant outbreaks of the pandemic. All sites examined represented verification environments close to the patient/point of care, and all verification operators reported having no prior education or laboratory experience. 100% of operators agreed that Veros COVID-19 was easy to use, read and results, with minimal handling time required from start to finish.
As the virus continues to evolve, Veros COVID-19 has remained one hundred percent in all variants of interest and fear known to date through the WHO and the U. S. CDC. In the U. S. , adding all Omicron subvariants.
See how it works here.
About sensory biodetection
Sense Biodetection is a global molecular diagnostics company whose goal is to empower patients and transform healthcare access and affordability by delivering lab-quality effects through easy-to-use, fast, and disposable molecular testing without the limitations of an instrument. The company’s Veros product platform will enable large-scale testing to improve patient access, improve patient health, and reduce systemic healthcare costs. Backed by accredited investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has unveiled its first product, Veros COVID-19, and is developing while building a portfolio of tests for other diseases.
About TECOmedical
Headquartered in Switzerland, TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria, is a leading provider of specialized in vitro analysis systems for medical diagnosis, in immunosorbent, immunofluorescent and molecular methodologies.
For more information, visit https://sense-bio. com/ and join the company on Twitter and LinkedIn.
See the businesswire. com edition: https://www. businesswire. com/news/home/20220901005154/en/
Contacts
Media: Mike Sinclair Halsin Partners 7968 022075 msinclair@halsin. com
Fuckyou